![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The comapany will use the received grant for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines and further optimize the hits to in vivo lead compounds during the hit-to-lead process.
Lead Product(s): Undisclosed
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Funding September 20, 2022